Engflag

Avamina

Quick links to important sections

Avamina

Avamina_EN

Method of action: Drugs Used In Diabets, Hypoglycemic

Treatment option: Change Of Life, Obesity, Diabetes Mellitus, Type 2 Diabetes

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Avamina

Property Description
Active ingredient Metformin Hydrochloride
Form Oral Tablet (Immediate-release and Extended-release)
Pharmacological class Biguanide
Common use Improving Glucose Tolerance
Origin Synthetic

What Type of Medicine is Avamina (Metformin)?

Avamina is a synthetic oral medication primarily identified by its active pharmaceutical ingredient, Metformin Hydrochloride. It is classified as an antihyperglycemic agent belonging to the biguanide class, clinically recognized for its role in managing blood sugar. As a foundational therapy, it is recognized for its ability to improve overall glycemic control and metabolic health.

The medication's distinction lies in its mechanism, which operates without directly increasing the body's insulin secretion, a feature that separates it from secretagogue agents. This characteristic is relevant when initiating oral treatment for adult and pediatric patients (10 years of age and older) requiring assistance with glucose tolerance.

Composition and Available Forms of Avamina

The core composition of Avamina consists of the Metformin Hydrochloride active ingredient, combined with solid oral excipients for oral administration. Avamina is a single-entity product supplied as an oral tablet and is available in both immediate-release (IR) and extended-release (XR) versions. The design of the extended-release formulation provides a sustained pharmacological effect, which is intended to enhance patient adherence and reduce gastrointestinal side effects compared to the immediate-release tablet.

General Purpose and Functional Distinction

The general purpose of Avamina is to lower chronically high blood sugar levels. Its functional distinction involves two key processes: it significantly helps to decrease hepatic glucose production and enhances insulin sensitivity in peripheral tissues. This combination of effects stabilizes blood sugar without directly stimulating the pancreas. This is particularly useful in patients with underlying insulin resistance, where the body's cells do not effectively respond to naturally produced insulin.

What side effects are possible with Avamina?

Possible Side Effects and Safety Information

Avamina, which contains the active ingredient metformin, is generally well-tolerated, but like all medications, it can cause side effects. Awareness of these is important for patient safety.

Common Side Effects

Side effects that are very common (may affect more than 1 in 10 people) or common (may affect up to 1 in 10 people) often involve the digestive system and typically diminish over time as the body adjusts to the medication. Taking Avamina with or after a meal can help reduce these effects.

Classification Side Effect What to do
Very Common Nausea, vomiting, diarrhea, stomach pain, loss of appetite Speak to your doctor if symptoms persist or worsen.
Common Metallic taste in the mouth, headache Usually mild and temporary.

Serious Warnings and Precautions

Lactic Acidosis

Lactic acidosis is a rare but serious metabolic complication that can be life-threatening if untreated. The risk is increased if you have significantly impaired kidney function, severe infection, acute heart failure, or if you consume excessive alcohol.

Seek immediate medical attention if you experience symptoms such as deep, rapid breathing, vomiting, severe abdominal pain, muscle cramps, feeling cold, extreme tiredness, or dizziness.

Vitamin B12 Deficiency

Long-term use of Avamina may lead to a decrease in Vitamin B12 levels. Your doctor may perform regular blood tests to monitor this and may recommend supplements if a deficiency is detected. Untreated deficiency can lead to anemia and nerve damage (neuropathy).

Contraindications

Avamina should not be taken if you have a known allergy to metformin, severe kidney problems, uncontrolled diabetes with ketoacidosis, acute heart failure, or if you consume large amounts of alcohol.

Overdose and Emergency Response

Overdose and When to Seek Help

The most serious and life-threatening outcome associated with Avamina overdose or drug accumulation is Lactic Acidosis. This severe metabolic crisis requires immediate medical intervention due to its potential to cause cardiovascular collapse and death. Official regulatory documents list early overdose presentations as nonspecific symptoms that may include malaise, muscle pain (myalgias), increasing somnolence (drowsiness), hypotension, and gastrointestinal distress such as nausea and vomiting.

If any of these signs appear, it is mandatory to seek immediate emergency medical attention. Patients or caregivers must immediately discontinue Avamina. The established emergency protocol, based on regulatory guidance, requires the institution of general supportive measures in a hospital setting. Lactic Acidosis is characterized by highly elevated blood lactate levels (e.g., above 5 mmol/L) and severe anion gap acidosis. As no specific antidote is known, prompt hemodialysis is recommended as the definitive procedural intervention to remove the accumulated medicine and correct the metabolic imbalance. The risk of accumulation leading to this life-threatening event is increased in individuals with severe renal impairment, hepatic insufficiency, or advanced age.

Therapeutic Uses of Avamina

Avamina is used to support the management and assist in controlling high blood glucose levels in adults, children, and adolescents diagnosed with type 2 diabetes mellitus. This medication is typically part of a comprehensive management plan that includes diet and exercise, and it is commonly used when these lifestyle measures alone are insufficient for blood sugar regulation.

The authorized indications for Avamina include: the management of type 2 diabetes in adults (used alone or in combination with other antidiabetic therapies or insulin), the management of type 2 diabetes in children and adolescents from 10 years of age (alone or combined with insulin), providing support for individuals with prediabetes, and the management of Polycystic Ovary Syndrome (PCOS). The primary benefit is assistance in reducing elevated blood sugar values to help support the overall condition management.

Quick Fact: Relief for Elevated Blood Sugar

Eligibility and Restrictions for Use

Avamina (Metformin) is officially designated for use in adults and pediatric patients ge 10 years of age with Type 2 Diabetes Mellitus. Eligibility is strictly governed by a series of absolute contraindications and conditional restrictions documented in regulatory labeling.

Contraindicated Populations

Use of Avamina is prohibited in patients with severe renal impairment (e.g., eGFR < 30 mL/min/1.73 m^2) or known hypersensitivity to the medicine. It is also contraindicated in patients with acute or chronic metabolic acidosis (including diabetic ketoacidosis), severe hepatic impairment, or conditions that may cause tissue hypoxia, such as acute heart failure or respiratory failure.

Condition-Based Restrictions

Classification Regulatory Requirement
Moderate Renal Impairment Initiation is not recommended if eGFR is 30–45 mL/min/1.73 m^2. Use in older adults requires more frequent renal function assessment.
Surgical/Radiological Procedures The medicine must be temporarily suspended prior to or at the time of an imaging procedure involving iodinated contrast agents or major surgery, and withheld for a defined period afterwards.
Pregnancy and Lactation Use is generally not recommended or restricted. Alternative agents (e.g., insulin) may be preferred during pregnancy, as stated in some official documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Avamina (Metformin) interaction patterns are defined primarily by its clearance mechanism and potential additive metabolic effects, as documented by regulatory agencies. Co-administration constraints are grouped into exposure-altering, pharmacodynamic, and contraindicated interactions.

Pharmacokinetic and Exposure-Altering Interactions

Avamina is primarily eliminated via renal tubular secretion mediated by Organic Cation Transporters (OCTs). Co-administration with certain cationic drugs (e.g., Cimetidine, Ranolazine, Dolutegravir) inhibits these transporters, resulting in reduced renal clearance and a significant increase in Avamina plasma concentration.

Pharmacodynamic and Risk-Potentiating Interactions

Interacting Substance/Class Documented Outcome
Iodinated Contrast Agents Contraindicated in patients with severely reduced kidney function due to high risk of drug accumulation and lactic acidosis. Requires temporary cessation.
Excessive Alcohol Potentiates effects on lactate metabolism, significantly increasing the risk of lactic acidosis.
Glucocorticoids/Diuretics Can cause hyperglycemia, counteracting Avamina's effects and leading to a loss of glycemic control.
Carbonic Anhydrase Inhibitors Increases the risk of metabolic acidosis, which adds to the potential for Metformin-associated lactic acidosis.

Food Interactions

The immediate-release formulation's absorption is officially documented to be decreased and delayed when taken with food.

Mechanism of Action

Avamina exerts its action by inhibiting the enzyme Farnesyl Pyrophosphate Synthase (FPPS). This enzyme, a key component of the mevalonate pathway, catalyzes the conversion of farnesyl diphosphate into geranylgeranyl diphosphate. By blocking the catalytic activity of FPPS, Avamina selectively disrupts the synthesis of these intermediary lipid molecules within the cell. The subsequent lack of these intermediates prevents the necessary prenylation of small signaling GTPases, including the Ras and Rho protein families. Prenylation is the process of attaching a lipid anchor required for these proteins to correctly localize to the inner face of the cell membrane. Consequently, Avamina's activity results in the mislocalization of these essential GTPases to the cytosol. This mislocalization effectively impairs their ability to participate in membrane-anchored signaling cascades, ultimately modulating cellular processes that rely on their proper function.

Dosage and Administration Information

How to Use Avamina

The usage of Avamina (Metformin Hydrochloride) involves specific parameters for administration, dosing, and timing. This medicine is administered exclusively by the oral route as either an Immediate-Release (IR) tablet or an Extended-Release (XR) tablet.

Official Administration Guidelines

Property Administration Requirements
Dosing Frequency The IR tablet is typically taken in divided doses two or three times daily, whereas the XR tablet is primarily taken once daily.
Timing with Meals The IR tablet must be taken with meals to minimize gastrointestinal discomfort. The XR tablet is generally advised to be taken once daily with the evening meal.
Titration Schedule Treatment initiation follows a gradual titration schedule. Starting doses (e.g., 500 mg BID for IR) are increased incrementally (e.g., in 500 mg amounts) at specified intervals (e.g., weekly or biweekly) based on tolerability, up to a maximum daily dose of 2550 mg.
Handling Constraints Extended-release tablets must be swallowed whole; they are not to be crushed, cut, dissolved, or chewed, as this action compromises the sustained pharmacological effect.

Population-Specific Use

Specific parameters apply to the use of this medication in certain groups. For pediatric patients (age 10 and older), the starting dose is 500 mg twice daily, with a maximum of 2000 mg per day in divided doses. Importantly, therapy is contraindicated or not recommended below specific thresholds of renal function (e.g., eGFR ≤ 30 mL/min/1.73 m^2). Furthermore, Avamina is temporarily discontinued at the time of, or prior to, certain imaging procedures involving iodinated contrast agents.
Missed Dose If a dose is missed, it should be skipped, and the next dose should be taken at the regularly scheduled time. Double doses should be avoided.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Landscape for the Drug

Research has evaluated the drug's role in individuals experiencing moderate to severe symptoms of Condition X. The existing body of evidence includes a combination of randomized controlled trials (RCTs) and long-term observational studies. Studies generally focused on primary endpoints related to symptom severity, measured by the X-Symptom Severity Index (XSSI), and secondary endpoints such as patient-reported quality of life.

Key Study Findings

RCT 1: Evaluation of Outcomes and Quality of Life

One key study investigated the drug's effect on quality of life and the frequency of flare-ups. The study reported findings related to quality of life and flare-up frequency. The trial protocol outlined specific guidance for participants regarding treatment continuation and cessation.

  • Endpoint 1 (XSSI Score): Participants receiving the drug exhibited a difference in average XSSI score compared to the placebo group.
  • Endpoint 2 (Quality of Life): Patient-reported outcomes related to daily functioning were assessed.
  • Onset of Reported Changes: Research examined the onset of reported changes within the first week of use. A comparison was made to findings for standard care.

Study 2: Long-term Symptom Assessment

A non-placebo-controlled study investigated the measurement of symptom severity over a six-month period. This study focused on patients who had previously responded to the initial treatment phase.

  • Follow-up: Participants were monitored monthly using objective clinical markers.

Combination Therapy Trials

A combination therapy trial evaluated the effect of the drug paired with Therapy Y, and compared the reported outcomes to the outcomes of each treatment alone.

  • Trial Goal: Research evaluated whether the combination of the drug and Therapy Y yielded different outcomes than either treatment as a monotherapy.

Conclusion of Evidence Overview

The drug is part of a therapeutic class. Research evaluated this class in individuals whose current treatment was not meeting therapeutic goals. Overall, the research includes the results from multiple trials investigating the drug's role in Condition X.

Frequently Asked Questions (FAQ)

Common questions about Avamina (FAQ)

Q: What is Avamina used to treat?

Avamina is approved for use in adults to treat Type 2 Diabetes Mellitus. It is used in addition to diet and exercise to help improve blood sugar control. According to official regulatory documents, it belongs to a class of medicines known as selective sodium-glucose cotransporter-2 (SGLT2) inhibitors.

Q: Does Avamina cause weight loss?

Studies and official information indicate that weight loss can be a secondary effect experienced by some patients taking Avamina. This effect is thought to be related to the way the medicine works by promoting the elimination of sugar through urine. The medicine's primary approved purpose, according to regulatory labeling, remains the control of blood sugar in adults with Type 2 Diabetes.

Q: Is Avamina the same as insulin?

No, Avamina is not the same as insulin. Avamina works in the kidneys by blocking a protein called SGLT2, which helps the body remove excess glucose (sugar) through the urine. Insulin is a hormone produced by the pancreas that helps cells absorb glucose for energy. Regulatory documents state that Avamina can be used alone or in combination with other diabetes medications, including insulin, as prescribed by a healthcare provider.

Q: Can I stop taking Avamina if my blood sugar levels improve?

Official product information emphasizes that Avamina is typically part of a long-term treatment plan for chronic Type 2 Diabetes. Although blood sugar may improve, regulatory documents indicate that patients should consult with a healthcare professional regarding any decision to continue, stop, or change their prescribed therapy. The decision to alter treatment should always be made by a prescribing clinician.

How should Avamina be stored and disposed of?

Official Storage and Disposal Information

Storage and disposal requirements for Avamina are defined by regulatory labeling to ensure product quality and safety. The medicine must be stored at controlled room temperature, typically between 20 C and 25 C, and protected from both excessive heat and freezing.

Protect the product from light and moisture by keeping it in the original container with the cap tightly closed. It is mandatory to keep Avamina out of the reach and sight of children at all times.

Disposal

Official instructions prohibit the disposal of unused or expired Avamina by flushing it down a toilet or pouring it down a drain. To properly dispose of the medicine, return it to a pharmacy or an authorized medication take-back program in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPoland

Equivalent of Avamina found in:

A-Z Index: